Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cardiovascular-kidney-metabolic (CKM) syndrome involves multiple organ systems and is associated with a graded increase in mortality risk across stages. Stage 2 includes individuals with metabolic risk factors and/or moderate- to high-risk chronic kidney disease (CKD) without subclinical or clinical cardiovascular disease, representing nearly half of US adults. This study aimed to develop and validate a simple model based on easily assessable parameters to stratify CKM syndrome stage 2 into two risk groups, in order to improve patient care and prevent cardiovascular events and mortality.
We analyzed adult participants from the 1999-2018 National Health and Nutrition Examination Survey (NHANES) linked to the US National Death Index, selecting those with CKM syndrome stage 2 and dividing the sample into development and validation cohorts. Variables were selected using modified LASSO regression and multivariable Cox proportional hazards models, with cardiovascular death as the outcome. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC) and the C-statistic, with survival analyses also performed to evaluate discrimination. Calibration tests and internal validation were conducted to evaluate model performance. TriNetX database with de-identified aggregated patient-level data from medical records was analyzed to evaluate the clinical implications of the model, using major adverse cardiovascular events (MACE) as outcome.
We developed a sex-specific model. Women classified as higher risk (stage 2b) meet at least two of the following criteria: age ≥ 66 years, CKD, diabetes, and hypertension (time-dependent AUC 0.79; C-index 0.78); men classified as higher risk (stage 2b) meet at least two of the following: age ≥ 61 years, CKD, diabetes, and smoking (time-dependent AUC 0.73; C-index 0.72). External validation confirmed preserved cardiovascular risk discrimination (women: time-dependent AUC 0.75; men: time-dependent AUC 0.77) with significantly distinct 10-year cumulative incidence of cardiovascular death. When applied the model to TriNetX cohort, women in stage 2a had a 10-year-risk of 11.3% (95% CI 10.0 to 12.6) compared to 24.6% (95% CI 24.0 to 25.2) in stage 2b, while men’s risk increased from 13.1% (95% CI 12.7 to 13.6) to 30.8% (95% CI 30.0 to 31.5).
Stratification of CKM syndrome stage 2 using our model facilitates individualized risk assessment and targeted management, enabling early interventions to prevent progression to advanced CKM syndrome stages, particularly among high-risk individuals.
